Common pathological processes in Alzheimer disease and type 2 diabetes: a review.
Alzheimer disease (AD) and type 2 diabetes mellitus (T2DM) are conditions that affect a large number of people in the industrialized countries. Both conditions are on the increase, and finding novel treatments to cure or prevent them are a major aim in research. Somewhat surprisingly, AD and T2DM share several molecular processes that underlie the respective degenerative developments. This review describes and discusses several of these shared biochemical and physiological pathways. Disturbances in insulin signalling appears to be the main common impairment that affects cell growth and differentiation, cellular repair mechanisms, energy metabolism, and glucose utilization. Insulin not only regulates blood sugar levels but also acts as a growth factor on all cells including neurons in the CNS. Impairment of insulin signalling therefore not only affects blood glucose levels but also causes numerous degenerative processes. Other growth factor signalling systems such as insulin growth factors (IGFs) and transforming growth factors (TGFs) also are affected in both conditions. Also, the misfolding of proteins plays an important role in both diseases, as does the aggregation of amyloid peptides and of hyperphosphorylated proteins. Furthermore, more general physiological processes such as angiopathic and cytotoxic developments, the induction of apoptosis, or of non-apoptotic cell death via production of free radicals greatly influence the progression of AD and T2DM. The increase of detailed knowledge of these common physiological processes open up the opportunities for treatments that can prevent or reduce the onset of AD as well as T2DM.
Li
Lin
L
Gerontology Institute, Shanxi Medical University, #86 South Xin Jian Road (030001), Taiyuan, Shanxi, China.
Hölscher
Christian
C
D000544:Alzheimer Disease / Q000453:epidemiology / Q000473:pathology*; D000682:Amyloid / Q000378:metabolism; D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology / Q000473:pathology*; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000502:physiology; D016874:Neurofibrillary Tangles / Q000473:pathology; D016212:Transforming Growth Factor beta / Q000378:metabolism; D016875:tau Proteins / Q000378:metabolism
D000682:Amyloid; D017127:Glycation End Products, Advanced; D007328:Insulin; D016212:Transforming Growth Factor beta; D016875:tau Proteins